Camp4 Therapeutics Corp (CAMP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US13463J1016
Camp4 Therapeutics Corp financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3.50 m USD |
| Operating income | -52.56 m USD |
| EBIT | -82.58 m USD |
| Net income | -80.40 m USD |
| Diluted EPS – continuing operations | -2.65 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Camp4 Therapeutics Corp
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
More stocks
- Nuveen Core Plus Impact Fund (NPCT)
- Protalix BioTherapeutics, Inc. (PLX)
- Zhejiang Sanfer Electric Co. Ltd (605336.SS)
- VIA Labs Inc (6756.TW)
- Anhui Hyea Aromas Co Ltd (300886.SZ)
- Nano Dimension Ltd. (NNDM)
- NACCO INDUSTRIES INC (NC)
- STI Co. Ltd (039440.KQ)
- Dah San Electric Wire & Cable Co Ltd (1615.TW)
- ADM Korea Inc. (187660.KQ)
- Seaport Entertainment Group Inc. (SEG)
- Sphera Franchise Group SA MiFID Eligible Security (SFG.RO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.